It was found that the Hb level, WHO stage and chromosome karyotype of patients before treatment had a significant impact on the treatment effect of MDS and the treatment effect of patients with Hb<90 g / L, RAEB-1 stage and bad chromosome karyotype was often poor. Here, GSTM1 is linked to myelodysplastic syndrome.